Survodutide

Synonyms: BI 456906, GLP-1/Glucagon receptor agonist, 2805997-46-8

Survodutide (BI 456906) is a synthetic peptide dual agonist targeting both the glucagon-like peptide-1 (GLP-1) and glucagon receptors. Developed by Boehringer Ingelheim, it is currently in clinical trials for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The peptide is designed to activate both incretin and glucagon signaling pathways, which together enhance energy expenditure and promote weight loss.

As a research-grade chemical, Survodutide is supplied in lyophilized powder form for laboratory use only. It is not intended for human or veterinary use, but serves as a valuable tool for studying the therapeutic potential of dual GLP-1/glucagon agonism in metabolic diseases.

Zastosowania

• Obesity research: Investigating mechanisms of weight loss and energy metabolism.
• Metabolic disease studies: Exploring effects on insulin sensitivity and lipid profiles.
• MASH research: Evaluating potential for treating non-alcoholic steatohepatitis.
• Peptide pharmacology: Understanding dual receptor agonism and downstream signaling.

Zamówienia i dostawy

• Opakowanie: Available in vials or bulk containers, custom packaging on request.
• MOQ: 5 g
• Czas realizacji: Typically 1-2 weeks after order confirmation.
• Dokumentacja: COA, MSDS, and TDS provided with each shipment.

Zapytanie ofertowe

• Nasz adres: 280 Main Street, Xi’an, Shaanxi, Chiny
• LyvBio Sp. z o.o. — E-mail: info@lyvbio.com